Christopher J. Schaber

Dr. Christopher J. Schaber is presently Chairman, President and CEO of Soligenix, Inc. (NASDAQ:SNGX), a rare disease biotechnology company developing drug therapies for multiple orphan diseases, which includes a Phase III pivotal clinical trial for cutaneous T-cell lymphoma and a Phase III pivotal trial for oral mucositis in head and neck cancer. Dr. Schaber has spent his 28-year career dedicated to the development of drug therapies in rare diseases and areas of unmet medical need.